Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 4Vomiting 3Nausea 2Anorexia 2Weight Loss 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Opioid-Related Disorders 1Muscular Atrophy 1Multiple Myeloma 1Lung Neoplasms 1Hematologic Neoplasms 1Gynecologic Cancer 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Child Nutrition Disorders 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1

Interventions

gadobutrol 1fosaprepitant 1Surveys and Questionnaires 1Standard of Care 1Prochlorperazine 1Ondansetron 1Olanzapine 1Neurokinin-1 Receptor Antagonists 1Imagery, Psychotherapy 1Dexamethasone 1Cryotherapy 1Brachytherapy 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gynecologic Cancer × Olanzapine × 1 year × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡